MaxCyte, Inc. (MXCT) DCF Valuation

Maxcyte, Inc. (MXCT) DCF Valoración

US | Healthcare | Medical - Devices | NASDAQ
MaxCyte, Inc. (MXCT) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

MaxCyte, Inc. (MXCT) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Descubra el verdadero potencial de MaxCyte, Inc. (MXCT) con nuestra calculadora DCF avanzada! Ajuste los supuestos clave, explore varios escenarios y evalúe cómo las diferentes variables afectan la valoración de Maxcyte, todo dentro de una plantilla integral de Excel.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 21.6 26.2 33.9 44.3 41.3 49.0 58.1 68.9 81.7 96.9
Revenue Growth, % 0 21.04 29.52 30.59 -6.72 18.61 18.61 18.61 18.61 18.61
EBITDA -11.6 -9.9 -16.8 -20.9 -44.1 -28.2 -33.5 -39.7 -47.1 -55.9
EBITDA, % -53.65 -38 -49.46 -47.16 -106.88 -57.65 -57.65 -57.65 -57.65 -57.65
Depreciation .6 1.0 1.4 2.7 4.2 2.7 3.2 3.8 4.5 5.3
Depreciation, % 2.84 4 4.2 6.1 10.1 5.45 5.45 5.45 5.45 5.45
EBIT -12.2 -11.0 -18.2 -23.6 -48.3 -29.9 -35.5 -42.1 -49.9 -59.2
EBIT, % -56.49 -42 -53.66 -53.25 -116.98 -61.08 -61.08 -61.08 -61.08 -61.08
Total Cash 16.7 34.8 255.0 227.3 168.3 46.7 55.4 65.8 78.0 92.5
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 3.2 5.2 6.9 11.2 5.8
Account Receivables, % 15.01 19.76 20.29 25.25 13.99
Inventories 3.7 4.3 5.2 8.6 12.2 9.6 11.4 13.5 16.0 19.0
Inventories, % 17.12 16.49 15.36 19.39 29.62 19.59 19.59 19.59 19.59 19.59
Accounts Payable 2.1 .9 1.8 .3 .7 2.0 2.4 2.9 3.4 4.0
Accounts Payable, % 9.66 3.4 5.37 0.65972 1.8 4.18 4.18 4.18 4.18 4.18
Capital Expenditure -1.3 -2.1 -3.8 -18.5 -3.7 -7.4 -8.8 -10.4 -12.4 -14.7
Capital Expenditure, % -5.88 -7.92 -11.31 -41.75 -8.96 -15.16 -15.16 -15.16 -15.16 -15.16
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -12.9 -11.8 -19.2 -19.8 -48.3 -28.9 -34.3 -40.7 -48.3 -57.3
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -18.4 -16.5 -23.3 -44.8 -45.6 -33.2 -43.1 -51.1 -60.6 -71.9
WACC, % 9.69 9.69 9.69 9.66 9.69 9.69 9.69 9.69 9.69 9.69
PV UFCF
SUM PV UFCF -192.0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -73
Terminal Value -954
Present Terminal Value -601
Enterprise Value -793
Net Debt -28
Equity Value -765
Diluted Shares Outstanding, MM 103
Equity Value Per Share -7.41

What You Will Receive

  • Pre-Filled Financial Model: MaxCyte’s actual data facilitates accurate DCF valuation.
  • Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential metrics.
  • Real-Time Calculations: Automatic updates provide immediate results as you adjust inputs.
  • Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
  • Flexible and Reusable: Designed for adaptability, allowing for repeated use in detailed forecasting.

Key Features

  • Comprehensive Financial Data: Gain access to precise historical performance and future forecasts for MaxCyte, Inc. (MXCT).
  • Adjustable Forecast Parameters: Modify highlighted cells for key metrics like WACC, growth rates, and profit margins.
  • Real-Time Calculations: Instant updates for DCF, Net Present Value (NPV), and cash flow assessments.
  • User-Friendly Dashboard: Clear charts and summaries to help you interpret your valuation findings.
  • Designed for All Skill Levels: A straightforward, intuitive layout tailored for investors, CFOs, and consultants alike.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered MaxCyte, Inc. (MXCT) data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for MaxCyte, Inc. (MXCT)’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for MaxCyte, Inc. (MXCT)?

  • Designed for Experts: A sophisticated tool tailored for analysts, CFOs, and industry consultants.
  • Accurate Financial Data: MaxCyte's historical and projected financials are preloaded to ensure precision.
  • Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
  • Comprehensive Outputs: Instantly calculates intrinsic value, NPV, and essential metrics.
  • User-Friendly Interface: Step-by-step guidance simplifies the entire calculation process.

Who Should Use This Product?

  • Investors: Accurately assess MaxCyte, Inc.'s (MXCT) fair value prior to making investment choices.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to MaxCyte, Inc. (MXCT).
  • Consultants: Effortlessly modify the template for valuation reports tailored to MaxCyte, Inc. (MXCT) clients.
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms like MaxCyte, Inc. (MXCT).
  • Educators: Implement it as a teaching resource to illustrate valuation techniques relevant to MaxCyte, Inc. (MXCT).

What the Template Contains

  • Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for MaxCyte, Inc. (MXCT).
  • Real-World Data: MaxCyte's historical and projected financials preloaded for in-depth analysis.
  • Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into MaxCyte's performance.
  • Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to MaxCyte, Inc. (MXCT).
  • Dashboard with Visual Outputs: Charts and tables providing clear, actionable results for stakeholders.

No products were found matching.